Aquestive Therapeutics Inc (AQST)
Cost of Revenue
$17.83M
TTM · Period ending: · USD
AQST Cost of Revenue
Latest reported$17.83Mperiod ending
Latest reported$17.83Mperiod ending
AQST TTM Cost of Revenue ($19.82M → $17.83M)
TTM cost of revenue
High-resolution chart · PNG
AQST cost of revenue history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Cost of Revenue (USD) |
|---|---|
| 17,828,000 | |
| 18,372,000 | |
| 18,555,000 | |
| 17,239,000 | |
| 17,170,000 | |
| 17,135,000 | |
| 17,872,000 | |
| 18,031,000 | |
| 18,392,000 | |
| 20,483,000 | |
| 20,831,000 | |
| 21,457,000 | |
| 21,284,000 | |
| 19,909,000 | |
| 19,386,000 | |
| 17,447,000 | |
| 17,222,000 | |
| 16,446,000 | |
| 14,989,000 | |
| 14,411,000 | |
| 12,989,000 | |
| 12,062,000 | |
| 12,964,000 | |
| 16,968,000 | |
| 18,633,000 | |
| 20,514,000 | |
| 20,361,000 | |
| 18,356,000 | |
| 19,305,000 | |
| 18,858,000 | |
| 20,988,000 | |
| 21,816,000 | |
| 21,104,000 | |
| 21,272,000 | |
| 19,820,000 |